Pfizer to broaden diversity of COVID-19 vaccine trial
An amended protocol submitted to the FDA by Pfizer and BioNTech seeks to expand enrollment in a late-stage trial evaluating the companies' COVID-19 vaccine from 30,000 to 44,000 participants to include participants as young as 16, more people of color, and those with chronic, stable HIV, hepatitis C or hepatitis B. The companies have a 60% chance of determining whether the vaccine is effective by the end of next month, according to Pfizer CEO Albert Bourla. Bloomberg (tiered subscription model) (9/13)
Read full article now.
Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!